2024-09-13T07:51:35-05:00 2023-12-31 871353108 EISNER ADVISORY GROUP LLC 733 THIRD AVENUE NEW YORK NY 100172703 990 2023-01-01 364825921 THE MARK FOUNDATION FOR CANCER RESEARCH (US) LTD MARK 6468665950 1350 AVENUE OF THE AMERICAS 2902 NEW YORK NY 10019 RYAN SCHOENFELD CEO 6468665950 2024-09-12 1 1 CANDICE METH P01306891 2129498700 2023 2024-08-08 14:25:15Z RYAN SCHOENFELD 1350 AVENUE OF THE AMERICAS 2902 NEW YORK NY 10019 40942533 0 X WWW.THEMARKFOUNDATION.ORG X 2015 NY ACCELERATE RESEARCH TO TRANSFORM PREVENTION, DIAGNOSIS AND TREATMENT OF CANCER. 6 5 11 0 0 0 55001677 39897754 0 0 363707 1030138 -19890 9740 55345494 40937632 33385418 29825753 0 0 2942345 3134023 0 0 571003 1686843 2249721 38014606 35209497 17330888 5728135 110652350 104492388 28107967 20015419 82544383 84476969 PARTNER WITH SCIENTISTS TO ACCELERATE RESEARCH THAT WILL TRANSFORM THE PREVENTION, DIAGNOSIS, AND TREATMENT OF CANCER THROUGH GROUND BREAKING SCIENCE CARRIED OUT BY INDIVIDUAL INVESTIGATORS, MULTI DISCIPLINARY TEAMS, AND EARLY STAGE COMPANIES IN THE U.S AND ABROAD. 0 0 33325890 29825753 THE FOUNDATION'S GRANTS REWARD INNOVATIVE THINKING THAT ADVANCES THE UNDERSTANDING OF CANCER BIOLOGY AND IMPROVES ONCOLOGY TREATMENT PARADIGMS. THE FOUNDATION SUPPORTS INDIVIDUAL INVESTIGATORS, AS WELL AS MULTIDISCIPLINARY COLLABORATIVE TEAMS CONDUCTING RESEARCH ACROSS CANCER TYPES. THE GRANTEES BECOME PART OF THE FOUNDATION'S NETWORK OF THE BEST SCIENTIFIC MINDS IN CANCER RESEARCH AND TECHNOLOGICAL INNOVATION. GRANT SUBMISSIONS UNDERGO RIGOROUS PEER REVIEW BY THE FOUNDATION'S SCIENTIFIC ADVISORY COMMITTEE OR RECOMMENDED SUBJECT MATTER EXPERTS AND ARE HELD TO THE STRICTEST STANDARDS OF SCIENTIFIC EXCELLENCE. 33325890 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 50 0 1 11 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X IAN LESSER 6468665950 1350 AVENUE OF THE AMERICAS SUITE NEW YORK NY 10019 ALEX KNASTER AS OF 423 DIRECTOR 1.00 X 0 0 0 ROSS LEVINE DIRECTOR 1.00 X 10000 0 0 NICOLA MENDEHLSON AS OF 523 DIRECTOR 1.00 X 0 0 0 PAUL POSPISIL DIRECTOR 1.00 X 0 0 0 OTMAR D WIESTLER AS OF 52023 DIRECTOR 1.00 X 0 0 0 RAYMOND DUBOIS EXECUTIVE CHAIRMAN OF THE BOARD 24.00 X X 560000 0 0 STUART THOMSON TO 323 DIRECTOR 1.00 X 0 0 0 KEVIN O'FLAHERTY TO 323 DIRECTOR 1.00 X 0 0 0 WILLIAM SHAPARD TO 423 DIRECTOR 1.00 X 0 0 0 RYAN SCHOENFELD CHIEF EXECUTIVE OFFICER 40.00 X 486888 0 67648 IAN LESSER AS OF 723 DIRECTOR FINANCE & ADMINISTRATION 40.00 X 67083 0 27777 S PATRICK LEWIS TO 923 HEAD OF FINANCE AND OPERATIONS 40.00 X 210970 0 54124 ANNA TURETSKY PRINCIPAL, VENTURE INVESTMENTS 40.00 X 291748 0 62324 REBECCA BISH-CORNELISSEN HEAD DISCOVERY/PRECLINICAL RESEARCH 40.00 X 310138 0 58907 AMY FEHIR HEAD OF DEVELOPMENT 40.00 X 106825 0 19706 JANICE LIN PORTFOLIO MGR, RESEARCH/INVESTMENTS 40.00 X 144253 0 24814 REBECCA LIU DIRECTOR, GRANTS ADMINISTRATION 40.00 X 182444 0 41050 ROBERT MAGIN ASSOCIATE SCIENTIFIC DIRECTOR 40.00 X 141590 0 24633 2511939 0 380983 9 0 1 0 THE APPOINTMENT GROUP 135 WEST 26TH STREET NEW YORK NY 10001 TRAVEL/EVENT CONSULT 395426 ARNOLD & PORTER KAYE SCHOLER LLP 601 MASSACHUSETTS AVE NW WASHINGTON DC 200013743 LEGAL SERVICES 166874 YOUR PART TIME CONTROLLER 1500 WALNUT STREET PHILADELPHIA PA 19102 ACCOUNTING 157018 WIPFLI 10000 INNOVATION DRIVE MILWAUKEE WI 53226 CRM CONSULTING 149136 LGH COMMUNICATIONS 45 FLINT AVENUE LARCHMONT NY 10538 COMMUNICATIONS 106345 5 39897754 39897754 1035039 1035039 4901 -4901 -4901 -4901 FOREIGN EXCHANGE GAIN 900099 9740 9740 9740 40937632 0 0 1039878 24556055 24556055 5269698 5269698 1828563 1272142 320641 235780 1007884 698931 169308 139645 20658 16945 2338 1375 152865 107158 37389 8318 124053 91378 20496 12179 238259 73514 164745 228212 228212 134902 16099 112270 6533 17238 699 15925 614 67786 30013 36069 1704 410442 297159 49664 63619 243830 192200 20268 31362 502777 469078 31687 2012 91069 65934 11019 14116 29309 29309 RECRUITING FEES 87753 52753 35000 PAYROLL PROCESSING FEES 18884 13672 2285 2927 179260 155215 8226 15819 35209497 33325890 1312604 571003 1638919 3483399 27815316 18877966 60000000 62373066 2598595 3029739 465309 136382 287926 192756 112526 95170 16289988 14916600 1731697 1580066 110652350 104492388 520030 625207 25951419 18102751 1636518 1287461 28107967 20015419 X 81544383 80853903 1000000 3623066 82544383 84476969 110652350 104492388 X 5728135 -4472006 676457 X 0 1 X 1 0 X 80000860 40000110 32001882 55001677 39897754 246902283 80000860 40000110 32001882 55001677 39897754 246902283 73784234 173118049 534064 182602 141133 363707 1035039 2256545 -4552 -19890 9740 -14702 249144126 0.69490 0.69690 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: FOREIGN EXCHANGE LOSSES GAINS - 2021 AMOUNT: $ -4,552. 2022 AMOUNT: $ -19,890. 2023 AMOUNT: $ 9,740. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 75850 40290 35560 212076 152466 59610 95170 PRIVATE PREFERRED STOCK 14916600 F 14916600 LEASE LIABILITY 1287461 1287461 X 36492026 -4472006 26400 -4445606 40937632 0 40937632 34559440 26400 1302037 1328437 33231003 1978494 1978494 35209497 PART X, LINE 2: THE FOUNDATION FOLLOWS THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (THE "FASB") ACCOUNTING STANDARDS CODIFICATION ("ASC") TOPIC 740, INCOME TAXES, AS IT RELATES TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. BECAUSE OF THE FOUNDATION'S GENERAL TAX-EXEMPT STATUS, MANAGEMENT BELIEVES, ASC TOPIC 740 HAS NOT HAD, AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON THE FOUNDATION'S FINANCIAL STATEMENTS. PART XII, LINE 2D - OTHER ADJUSTMENTS: ALLOWANCE FOR CREDIT LOSSES 1,302,037. PART XII, LINE 4B - OTHER ADJUSTMENTS: PRIOR YEAR AWARDS AMENDED/REFUNDED AND NETTED AGAINST CURRENT YEAR GRANT EXPENSE 1,978,494. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTMAKING 4741026 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTMAKING 250000 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTMAKING 188672 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 GRANTMAKING 90000 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM GRANTEE VISITS 15793 0 0 0 0 0 0 5285491 0 5285491 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 2437400 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 249712 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 302342 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 939063 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 182631 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 249767 WIRE 0 EAST ASIA AND THE PACIFIC RESEARCH 90000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 377510 WIRE 0 NORTH AMERICA RESEARCH 188672 WIRE 0 MIDDLE EAST AND NORTH AFRICA RESEARCH 250000 WIRE 0 9 1 0 0 0 0 0 0 PART I, LINE 2: THE FOUNDATION AWARDS RESERACH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE FOUNDATION'S SCIENTIFIC ADVISORY COMMITTEE AND OTHER HIGHLY REGARDED SCIENTISTS SPECIALIZING IN CANCER RESEARCH. THE FOUNDATION CLOSELY MONITORS THE PROGRESS OF EACH GRANT AWARDED. THERE IS FREQUENT COMMUNICATION BETWEEN GRANTEES AND FOUNDATION STAFF REGARDING THE PROGRESS OF EACH GRANT. IN THE CASE OF MULTI-YEAR GRANTS, PROGRESS IS VERIFIED BEFORE ADDITIONAL GRANTS ARE AWARDED. PART I, LINE 3: AMOUNTS REPORTED USING THE ACCRUAL METHOD OF ACCOUNTING. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BROOKLYN NY 10461 830621846 501(C)(3) 483811 0 RESEARCH ASPEN CANCER CONFERENCE INC 419 MEADOW COURT BASALT CO 81621 521746776 501(C)(3) 25000 0 RESEARCH BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 770303411 741613878 501(C)(3) 246366 0 RESEARCH BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS STREET BOSTON MA 02115 042312909 501(C)(3) 375000 0 RESEARCH CHILDREN'S NATIONAL MEDICAL CENTER 111 MICHIGAN AVENUE NW WASHINGTON DC 20010 521640403 501(C)(3) 127500 0 RESEARCH DAMON RUNYON WALTER WINCHELL FOUNDATION ONE EXCHANGE PLAZA NEW YORK NY 10006 131933825 501(C)(3) 306316 0 RESEARCH DANA FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 022150000 042263040 501(C)(3) 3362500 0 RESEARCH EMORY UNIVERSITY 1599 CLIFTON RD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 249886 0 RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 750000 0 RESEARCH GABRIELLE'S ANGEL FOUNDATION FOR CANCER RESEARCH 142 W 57TH STREET NEW YORK NY 10019 133916689 501(C)(3) 666666 0 RESEARCH INSTITUTE FOR ADVANCED STUDY 1 EINSTEIN DRIVE PRINCETON NJ 08540 210634988 501(C)(3) 136635 0 RESEARCH JOHNS HOPKINS UNIVERSITY 3910 KESWICKROAD N-4327B BALTIMORE MD 21211 520595110 501(C)(3) 1199404 0 RESEARCH MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 633223 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 100656007 131924236 501(C)(3) 2670000 0 RESEARCH NATIONAL BRAIN TUMOR SOCIETY INC 55 CHAPEL STREET SUITE 006 NEWTON MA 02458 043068130 501(C)(3) 10000 0 RESEARCH NEW YORK UNIVERSITY 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 714900 0 RESEARCH OREGON HEALTH AND SCIENCE UNIVERSITY 2525 SW 3RD AVENUE SUITE 245 PORTLAND OR 97201 931176109 501(C)(3) 750000 0 RESEARCH PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE CAMBRIDGE MA 02138 042103580 501(C)(3) 170000 0 RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA BERKELEY 2195 HEARST AVENUE BERKELEY CA 947201101 946002123 501(C)(3) 127500 0 RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 5082 WOLVERINE TOWER 3003 SOUTH STATE STREET ANN ARBOR MI 481091287 386006309 501(C)(3) 250000 0 RESEARCH RUNX1 FOUNDATION 1482 EAST VALLEY ROAD STE 137 SANTA BARBARA CA 93108 813557785 501(C)(3) 25622 0 RESEARCH SAMUEL WAXMAN CANCER RESEARCH FOUNDATION 420 LEXINGTON AVENUE NEW YORK NY 101700899 133020943 501(C)(3) 7500 0 RESEARCH SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE MA 818-R1 SEATTLE WA 98105 910564748 501(C)(3) 250000 0 RESEARCH ST JUDE CHILDREN'S RESEARCH HOSPITAL INC 262 DANNY THOMAS PLACE MEMPHIS TN 381053678 620646012 501(C)(3) 750000 0 RESEARCH STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501(C)(3) 2125000 0 RESEARCH THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)(3) 934158 0 RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST SUITE 425 SAN FRANCISCO CA 941430812 946036493 501(C)(3) 1587337 0 RESEARCH THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL 700 CHILDRENS DRIVE COLUMBUS OH 43205 316056230 501(C)(3) 127268 0 RESEARCH ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 749997 0 RESEARCH TRUSTEES OF COLUMBIA UNIVERSITY OF THE CITY OF NEW YORK 615 WEST 131 STREET 3RD FLOOR NEW YORK NY 10027 135598093 501(C)(3) 823349 0 RESEARCH UNIVERSITY OF KANSAS MEDICAL RESEARCH INSTITUTE 3901 RAINBOW BLVD KANSAS CITY KS 66160 481108830 501(C)(3) 750000 0 RESEARCH UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE 220 ARCH STREET ROOM 02-148 BALTIMORE MD 21201 526002033 501(C)(3) 37500 0 RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 191046284 231352685 501(C)(3) 377472 0 RESEARCH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 770307009 746001118 501(C)(3) 250000 0 RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER 1161 21ST AVE SOUTH D-3300 MEDICAL CENTER NORTH NASHVILLE TN 372325445 352528741 501(C)(3) 2000000 0 RESEARCH WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 364264 0 RESEARCH 36 PART I, LINE 2: THE FOUNDATION REQUIRES GRANT RECIPIENTS TO COMPLY WITH STATED TERMS AND CONDITIONS GOVERNING EACH RESEARCH PROGRAM AWARDED, INCLUDING THE SUBMISSION OF PROGRESS REPORTS. DISBURSEMENT OF FUNDS IS CONTINGENT UPON ACCEPTANCE OF THESE TERMS AND TIMELY SUBMISSION OF REPORTS. X X X 0 0 0 0 0 0 0 1 0 RAYMOND DUBOIS EXECUTIVE CHAIRMAN OF THE BOARD 560000 0 0 0 0 0 0 0 0 0 560000 0 0 0 RYAN SCHOENFELD CHIEF EXECUTIVE OFFICER 351288 0 135600 0 0 0 11550 0 56098 0 554536 0 0 0 REBECCA BISH-CORNELISSEN HEAD DISCOVERY/PRECLINICAL RESEARCH 250882 0 59256 0 0 0 2878 0 56029 0 369045 0 0 0 ANNA TURETSKY PRINCIPAL, VENTURE INVESTMENTS 235096 0 56652 0 0 0 7221 0 55103 0 354072 0 0 0 S PATRICK LEWIS TO 923 HEAD OF FINANCE AND OPERATIONS 156895 0 54075 0 0 0 2208 0 51916 0 265094 0 54075 0 REBECCA LIU DIRECTOR, GRANTS ADMINISTRATION 157372 0 25072 0 0 0 6671 0 34379 0 223494 0 0 0 JANICE LIN PORTFOLIO MGR, RESEARCH/INVESTMENTS 131377 0 12876 0 0 0 5126 0 19688 0 169067 0 0 0 ROBERT MAGIN ASSOCIATE SCIENTIFIC DIRECTOR 129542 0 12048 0 0 0 4956 0 19677 0 166223 0 0 0 PART I, LINE 7 STAFF BONUSES ARE AWARDED ON A DISCRETIONARY BASIS UPON THE RECOMMENDATION OF THE CHIEF EXCECUTIVE OFFICER AND APPROVAL BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 2 TWO MEMBERS OF THE BOARD ARE EMPLOYEES OF PAMPLONA CAPITAL MANAGEMENT LLC, BOTH DIRECTORS OF WHICH ROTATED OFF OF THE FOUNDATION'S BOARD DURING 2023. ALEX KNASTER (FOUNDER OF THE MARK FOUNDATION FOR CANCER RESEARCH (U.S.) LTD.) IS ALSO THE FOUNDER AND CEO OF PAMPLONA CAPITAL MANAGEMENT LLC. MR. KNASTER JOINED THE FOUNDATION'S BOARD DURING 2023. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FOUNDATION'S 990 IS PROVIDED TO THE BOARD OF DIRECTORS FOR REVIEW AND COMMENT PRIOR TO ITS ELECTRONIC FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C ALL MEMBERS OF THE BOARD OF DIRECTORS AND KEY MEMBERS OF MANAGEMENT ARE REQUIRED TO REVIEW THE CONFLICTS-OF-INTEREST POLICY AND SIGN IT ON AN ANNUAL BASIS. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE CHAIRMAN OF THE BOARD SERVES AS A STRATEGIC ADVISOR TO THE FOUNDATION, PROVIDING GOVERNANCE LEADERSHIP, WHICH INCLUDES OVERSEEING BOARD MEETINGS, GUIDING STRATEGIC DECISIONS, AND ENSURING COMPLIANCE WITH THE FOUNDATION'S BY-LAWS. ADDITIONALLY, THE EXECUTIVE CHAIRMAN OFFERS FUNDRAISING SUPPORT AND PERFORMS OTHER SERVICES TYPICALLY ASSOCIATED WITH SUCH A POSITION, SUCH AS MENTORING SENIOR LEADERSHIP AND REPRESENTING THE FOUNDATION IN EXTERNAL ENGAGEMENTS. THE FOUNDATION'S BOARD CONDUCTS AN ANNUAL REVIEW OF THE EXECUTIVE CHAIRMAN'S PROFESSIONAL FEE TO ENSURE IT IS COMPETITIVE. THIS REVIEW INCLUDES A COMPARISON OF FEES PAID BY SIMILARLY SIZED PEER ORGANIZATIONS IN THE SAME GEOGRAPHIC LOCATION FOR SIMILAR SERVICES, HELPING THE FOUNDATION ATTRACT AND RETAIN HIGH-CALIBER LEADERSHIP. THE CHIEF EXECUTIVE OFFICER'S COMPENSATION IS REVIEWED ON AN ANNUAL BASIS BY THE BOARD OF DIRECTORS USING COMPARABLE MARKET DATA. COMPENSATION OF KEY EMPLOYEES IS DETERMINED BY THE CHIEF EXECUTIVE OFFICER, AND APPROVED BY THE BOARD OF DIRECTORS ON AN ANNUAL BASIS, AS A PART OF THE FOUNDATION'S BUDGET PROCESS. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION'S FORM 990 IS AVAILABLE UPON REQUEST. GOVERNING DOCUMENTS ARE ONLY DISTRIBUTED INTERNALLY TO THE BOARD OF DIRECTORS AND MANAGEMENT. FORM 990, PART XI, LINE 9: AMENDED/RETURNED GRANTS AWARDED IN PRIOR YEARS 1,978,494. ALLOWANCE FOR CREDIT LOSSES -1,302,037.